Russell J. Howard
Link suggestions feature: 1 link added.
| ← Previous revision | Revision as of 05:48, 26 April 2026 | ||
| Line 32: | Line 32: | ||
In 2008, Howard left Maxygen to found [http://www.oakbio.com Oakbio Inc.] in 2009. He remains Chairman of Oakbio Inc. (doing business as [https://www.novonutrients.com NovoNutrients Inc].), in Sunnyvale, California, USA. NovoNutrients uses proprietary microbes for {{CO2}} capture from industrial processes. Industrial [[Greenhouse gas emissions|{{CO2}} emissions]] are used as sole carbon source and {{chem|H|2}} gas as sole energy source to manufacture bacterial biomass, or single cell protein, a source of high quality protein for aquaculture and in future, for human foods [http://www.novonutrients.com]. |
In 2008, Howard left Maxygen to found [http://www.oakbio.com Oakbio Inc.] in 2009. He remains Chairman of Oakbio Inc. (doing business as [https://www.novonutrients.com NovoNutrients Inc].), in Sunnyvale, California, USA. NovoNutrients uses proprietary microbes for {{CO2}} capture from industrial processes. Industrial [[Greenhouse gas emissions|{{CO2}} emissions]] are used as sole carbon source and {{chem|H|2}} gas as sole energy source to manufacture bacterial biomass, or single cell protein, a source of high quality protein for aquaculture and in future, for human foods [http://www.novonutrients.com]. |
||
Upon taking up residence in 2012 in Sydney, Australia, Howard became Executive Chairman of [https://neuclone.com NeuClone Pty. Ltd]., a clinical stage biotechnology company dedicated to development of biosimilars of monoclonal antibody drugs. |
Upon taking up residence in 2012 in Sydney, Australia, Howard became Executive Chairman of [https://neuclone.com NeuClone Pty. Ltd]., a clinical stage biotechnology company dedicated to development of biosimilars of [[monoclonal antibody]] drugs. |
||
In 2013 Howard joined Prima Biomed Pty. Ltd., based in Sydney, Berlin and Paris, later renamed [https://immutep.com Immutep Pty. Ltd]., as Non-Executive Director. In 2017 he took the role of Non-Executive Chairman and continues today in this role. Immutep develops novel immuno-oncology and autoimmune drugs based on its [[LAG3]] patent estate. |
In 2013 Howard joined Prima Biomed Pty. Ltd., based in Sydney, Berlin and Paris, later renamed [https://immutep.com Immutep Pty. Ltd]., as Non-Executive Director. In 2017 he took the role of Non-Executive Chairman and continues today in this role. Immutep develops novel immuno-oncology and autoimmune drugs based on its [[LAG3]] patent estate. |
||
